GNH USA

Europe — EMA

Ivabradina Teva Group (Ivabradine)

GNH USA supplies Ivabradina Teva Group (Ivabradine), a If channel inhibitor for chronic stable angina and heart failure with reduced ejection fraction.

Ivabradine

Request sourcing

1
Pack/s

What is Ivabradine?

Ivabradine, the active ingredient in Ivabradina Teva Group, is an If channel inhibitor presented as an oral tablet for systemic use. It selectively lowers heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradina Teva Group as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards, is manufactured under GMP conditions, and our distribution network ensures timely delivery across multiple continents.

What is Ivabradine used for?

Ivabradine is used in cardiovascular conditions that involve elevated heart rate.

- Chronic stable angina: reduces the frequency of angina attacks by lowering myocardial oxygen demand. - Heart failure with reduced ejection fraction: improves symptoms and may decrease hospitalisation rates. - Ischemic heart disease (coronary artery disease): helps control heart rate to lessen myocardial workload.

What are the side effects of Ivabradine?

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Phosphenes (luminous visual phenomena) - Bradycardia (slow heart rate) - Headache - Dizziness - Fatigue - Nausea

Serious or Rare Side Effects: - Severe bradycardia leading to syncope - Atrioventricular block - Worsening heart failure - Visual impairment (persistent disturbances) - Angioedema

What precautions apply to Ivabradine?

Before initiating therapy, clinicians should consider several safety aspects.

- Heart‑rate monitoring: check resting heart rate and discontinue if it falls below 50 bpm. - Hepatic impairment: use with caution in patients with moderate to severe liver disease. - Concomitant bradycardic agents: avoid combining with beta‑blockers or digoxin without close supervision. - Sick‑sinus syndrome or AV‑block: contraindicated in patients with these rhythm disorders. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

What does Ivabradine interact with?

Ivabradine may interact with several medicines that affect heart rate or its metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Other bradycardic agents (beta‑blockers, digoxin, verapamil): risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely): - Verapamil or diltiazem: may modestly raise ivabradine levels. - Quinidine: can increase plasma concentrations. - Amiodarone: may enhance bradycardic effect, requiring heart‑rate monitoring.

Frequently asked questions

What conditions is Ivabradina Teva Group used for?+
Ivabradina Teva Group contains ivabradine, which is prescribed for chronic stable angina and for heart failure with reduced ejection fraction. In both cases the drug works by lowering heart rate, helping to reduce chest pain episodes and improve heart‑failure symptoms.
How does ivabradine work to treat these conditions?+
Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. By inhibiting this current, the drug slows the spontaneous firing of the node, reducing heart rate without affecting contractility, which lessens myocardial oxygen demand.
What is the usual dose of Ivabradina Teva Group?+
The exact dose and dosing schedule are determined by the prescribing clinician based on the patient’s clinical status, heart‑rate response, and tolerance. Ivabradina Teva Group is supplied as a prescription‑only oral tablet, and dosing should follow the prescriber’s instructions.
Is Ivabradina Teva Group safe during pregnancy or breastfeeding?+
Safety data for ivabradine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.
How do I order Ivabradina Teva Group from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does ivabradine compare with beta‑blockers for heart‑rate control?+
Both ivabradine and beta‑blockers lower heart rate, but they act via different mechanisms. Ivabradine selectively inhibits the If current without affecting blood pressure or contractility, whereas beta‑blockers block adrenergic receptors and can also reduce blood pressure. Ivabradine may be chosen when beta‑blockers are contraindicated or not tolerated.
What are the recommended storage conditions for Ivabradina Teva Group?+
Store the tablets at room temperature, below 25 °C, in the original packaging. Keep them away from moisture, heat and direct sunlight to maintain product stability throughout its shelf life.
How is Ivabradina Teva Group administered?+
The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not crushed or chewed, unless the prescribing information specifically allows it.
What are the most serious risks associated with ivabradine therapy?+
Serious risks include severe bradycardia, atrioventricular block, syncope, and worsening heart failure. Patients should be monitored for symptoms such as dizziness, fainting, or palpitations, and the drug should be discontinued if heart rate falls below the safe threshold.
Who should not use Ivabradina Teva Group?+
Ivabradina Teva Group is contraindicated in patients with sick‑sinus syndrome, second‑ or third‑degree atrioventricular block, severe hepatic impairment, or those who are already on strong CYP3A4 inhibitors without appropriate dose adjustment. It should also be avoided in individuals with known hypersensitivity to ivabradine.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Ivabradine
Route
Oral Use
Manufacturer
Teva B.V
Origin
EU

Related products

Ivabradine 5 mg/1

Ivabradine 5 mg/1

Ivabradine · 5 mg

Ivabradine
TABLET, FILM COATED
Camber Pharmaceuticals, Inc.
USA
Ivabradine 7.5 mg/1

Ivabradine 7.5 mg/1

Ivabradine · 7.5 mg

Ivabradine
TABLET, FILM COATED
Camber Pharmaceuticals, Inc.
USA
Bivelen

Bivelen

Ivabradine

Delorbis Pharmaceuticals Limited
EU
Bixebra

Bixebra

Ivabradine

Krka-Farma D.O.O.
EU